Skip to main content
. 2012 Oct 5;19(12):811–817. doi: 10.1038/cgt.2012.69

Figure 4.

Figure 4

Combined Allovectin and anti-CTLA-4 antibody immunotherapy: Survival. Kaplan–Meier plots are presented for the study described in Figure 2. Data were compared using the logrank test. (a) control groups only; (b) control groups (gray) and Allovectin groups; (c) control groups (gray) and VCL-1005 groups; (d) control groups (gray) and dimyristyloxypropyl-3-dimethyl-hydroxyethyl ammonium/dioleoyl phosphatidylethanolamine (DMRIE/DOPE) groups. Groups receiving no antibody (a) or SHG-1 (b–d) are shown as dotted lines, while groups receiving 9H10 are shown as solid lines.